Living document: Medicaid coverage policies change frequently. This article reflects the most recent information available as of May 2026. State Medicaid formulary decisions are made independently and can change at any time. Always verify coverage directly with your state Medicaid program before making treatment decisions.
The explosion of GLP-1 prescriptions created a budget crisis for state Medicaid programs. These medications are expensive — even at negotiated rates, they can cost Medicaid programs hundreds of dollars per patient per month. When millions of newly eligible patients seek coverage simultaneously, the fiscal pressure becomes enormous.
The result has been a patchwork of coverage decisions that varies dramatically by state. Some states have embraced GLP-1 coverage as a long-term investment in reduced healthcare costs (obesity-related hospitalizations, diabetes management, cardiovascular events). Others have dropped or restricted coverage, viewing the short-term budget impact as unsustainable.
States That Have Dropped or Restricted GLP-1 Coverage for Weight Loss
| State | Action | Status |
|---|---|---|
| California | Dropped Medicaid coverage for anti-obesity medications | Coverage removed |
| New Hampshire | Removed GLP-1 weight loss coverage from Medicaid formulary | Coverage removed |
| Pennsylvania | Restricted GLP-1 coverage for weight loss indications | Coverage restricted |
| South Carolina | Dropped Medicaid GLP-1 coverage for obesity | Coverage removed |
States Considering Coverage Changes
| State | Status | Notes |
|---|---|---|
| Massachusetts | Under review | Considering restrictions on Medicaid GLP-1 coverage for weight loss |
| Rhode Island | Under review | Evaluating cost sustainability of continued coverage |
The Cost Pressure
The math behind these decisions is straightforward. A single Medicaid beneficiary on a GLP-1 medication for weight management costs the state program thousands of dollars per year in drug costs alone. Multiply that by tens of thousands of eligible beneficiaries, and the budget impact is measured in hundreds of millions of dollars annually for larger states.
Proponents of coverage argue that the long-term savings — reduced hospitalizations for heart attacks, strokes, kidney failure, diabetes complications, and joint replacements — more than offset the drug costs. But those savings materialize over years, while the drug costs hit the budget immediately. For state legislators facing annual budget cycles, the long-term argument is difficult to act on.
The Diabetes Distinction
An important nuance: most of the coverage removals specifically target GLP-1 medications prescribed for weight loss (obesity indication). Coverage for the same active ingredients prescribed for type 2 diabetes (Ozempic, Mounjaro) generally remains in place, because federal Medicaid law requires coverage of FDA-approved medications for medically accepted indications in most circumstances.
This creates a paradox. A Medicaid beneficiary with type 2 diabetes can receive semaglutide (as Ozempic) and lose weight as a side benefit. A Medicaid beneficiary with obesity but without diabetes may be unable to receive the same medication (as Wegovy) in states that have dropped coverage. The clinical distinction between these two use cases is increasingly blurry — obesity and type 2 diabetes share the same metabolic root — but the coverage distinction remains sharp.
The BALANCE Model: A Federal Lifeline?
The federal BALANCE Model, announced by CMS in December 2025, is designed to eventually provide a framework for Medicaid GLP-1 coverage. The Medicaid component is expected to begin as early as 2026, with the Medicare component (through the Part D Bridge) launching in July 2026.
However, the BALANCE Model is not a mandate. State participation is voluntary, and the program's long-term funding is subject to federal budget decisions. For Medicaid beneficiaries in states that have already dropped coverage, the BALANCE Model may eventually restore access — but timelines and terms remain uncertain.
What to Do If Your State Dropped Coverage
Check for diabetes eligibility. If you have type 2 diabetes or prediabetes in addition to obesity, your provider may be able to prescribe a GLP-1 medication under the diabetes indication, which may still be covered even in states that have dropped the obesity indication.
Appeal the decision. State Medicaid programs have appeals processes. If your provider documents medical necessity — particularly cardiovascular risk, kidney disease risk, or other comorbidities — an individual appeal may succeed even when the general formulary policy has changed.
Explore manufacturer patient assistance programs. Novo Nordisk and Eli Lilly both offer patient assistance programs for uninsured and underinsured patients. Eligibility varies, but these programs can significantly reduce out-of-pocket costs.
Consider cash-pay options. With oral Wegovy available at $149/month for the starting dose and LillyDirect offering Zepbound at $399/month, the cash-pay market is more accessible than ever for patients whose Medicaid coverage has been dropped.
Contact your state legislators. Coverage decisions are ultimately political. If GLP-1 coverage matters to you, your state representatives need to hear from you. Patient advocacy has been a significant factor in states that have maintained or restored coverage.
Find Affordable GLP-1 Access
Compare telehealth providers offering GLP-1 prescriptions with cash-pay pricing, manufacturer savings, and insurance support.
Compare Providers